Kyverna Therapeutics

KYTXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$440.944 M

$7.13 +1.28%

Close of 18 Sept 2026

Revenue

—

Not reported

Earnings

-$161.3M

Loss-making

Shares outstanding

61,843,444

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 159 →

#68Ginkgo BioworksDNA$507.0M
#69Eikon TherapeuticsEIKN$484.8M
#70Kyverna TherapeuticsKYTX$440.9M
#71Cabaletta BioCABA$432.3M
#72Zura BioZURA$427.4M

What if Kyverna Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.4T

$491,361.04

Per share 68,915× higher

Bitcoin $1.64T

$26,454.35

Per share 3,710× higher

Nvidia $5.36T

$86,617.22

Per share 12,148× higher

Or at a round number

$1.00B $2.00B $5.00B $10.0B

Where these numbers come from

Share counts and financials for Kyverna Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 19 Sept 2026. Read the methodology.